|Alder Biopharmaceuticals Inc -- USA Stock|| |
USD 12.3 0.05 0.4%
Co-Founder and Chief Scientific Officer
Dr. John A. Latham, Ph.D., is Chief Scientific Officer of the Company. Dr. Latham served as a director, senior director, and most recently as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994, Dr. Latham joined Darwin Molecular Corporationrationration, a firstgeneration genetodrug biotechnology company, as a founding director, where he served from 1994 to 1998. Dr. Latham was one of the early scientists hired by Gilead Sciences, Inc., a biopharmaceutical company, and, from 1989 to 1994, he was a member of a core group established to exploit novel oligonucleotidebased technologies
Age: 56 Ph.D
Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.
The company has return on total asset (ROA)
of (44.69) %
which means that it has lost $44.69 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (76.45) %
meaning that it created substantial loss on money invested by shareholders.
Alder BioPharmaceuticals, Inc., a clinicalstage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States and Australia. Alder Biopharmaceuticals Inc (ALDR) is traded on NASDAQ General Markets in USA. It is located in WASHINGTON, U.S.A and employs 113 people. Alder Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification.